- Recommendation ID
- TA263/1
- Question
- Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
- Number
- TA263
- Date issued
- August 2012
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 03/09/2012 |